XTL Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . XTL Biopharmaceuticals Ltd
XTLB Stock  USD 0.67  0.02  2.90%   
XTL Biopharmaceutica's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing XTL Biopharmaceutica's valuation are provided below:
Gross Profit
-2.3 M
Quarterly Earnings Growth
(0.76)
Market Capitalization
6.3 M
Enterprise Value Revenue
6.1402
Revenue
968 K
We have found one hundred twenty available fundamental gauges for XTL Biopharmaceuticals, which can be analyzed and compared to other ratios and to its peers. All investors should make sure to confirm all of XTL Biopharmaceuticals prevalent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself for the next two years. The current year's Market Cap is expected to grow to about 11.3 M. The current year's Enterprise Value is expected to grow to about 11.1 M

XTL Biopharmaceutica Total Revenue

385,605

Check XTL Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XTL Biopharmaceutica's main balance sheet or income statement drivers, such as Other Operating Expenses of 2.2 M, Research Development of 83.8 K or Total Operating Expenses of 1.9 M, as well as many indicators such as Price To Sales Ratio of 25.16, Dividend Yield of 0.0 or PTB Ratio of 2.67. XTL financial statements analysis is a perfect complement when working with XTL Biopharmaceutica Valuation or Volatility modules.
  
Build AI portfolio with XTL Stock
Check out the analysis of XTL Biopharmaceutica Correlation against competitors.

XTL Biopharmaceutica Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.9 M7.7 M9.4 M
Slightly volatile
Total Stockholder Equity8.1 M4.9 M7.9 M
Slightly volatile
Common Stock Shares Outstanding2.1 M2 M1.1 M
Slightly volatile
Liabilities And Stockholders Equity9.9 M7.7 M9.4 M
Slightly volatile
Other Stockholder Equity144.4 M162.5 M141.5 M
Slightly volatile
Total Liabilities1.6 M2.8 M1.3 M
Very volatile
Other Current Liabilities1.8 M1.7 M693.9 K
Pretty Stable
Total Current Liabilities1.1 M2 M893.8 K
Pretty Stable
Other Liabilities1.3 M1.2 M1.3 M
Very volatile
Accounts Payable167.6 K176.4 K352.8 K
Slightly volatile
Cash317.2 K333.9 K2.3 M
Slightly volatile
Non Current Assets Total8.7 M8.3 M2.7 M
Slightly volatile
Cash And Short Term Investments977.3 K1 M4.8 M
Slightly volatile
Net Receivables162.4 K89.1 K109 K
Slightly volatile
Common Stock Total Equity15.9 M15.2 M10.2 M
Slightly volatile
Short Term Investments660.1 K694.8 K2.5 M
Slightly volatile
Other Current Assets152.2 K88.2 K173 K
Slightly volatile
Property Plant And Equipment Gross1.7 K1.8 K63.8 K
Slightly volatile
Total Current Assets1.1 M1.2 M5.1 M
Slightly volatile
Common Stock27.9 M26.6 M12.4 M
Slightly volatile
Property Plant Equipment85590075.1 K
Slightly volatile
Intangible Assets3.6 M3.4 M1.6 M
Very volatile
Current Deferred Revenue15.4 K16.2 K43.2 K
Slightly volatile
Short Term Debt118 K124.2 K329.9 K
Slightly volatile
Short and Long Term Debt Total118 K124.2 K352 K
Slightly volatile
Net Tangible Assets4.6 M4.2 M4 M
Slightly volatile
Capital Surpluse119 M132.9 M145.6 M
Slightly volatile
Net Invested Capital4.2 M5 M4.5 M
Slightly volatile
Capital Stock16.5 M26.6 M14.9 M
Slightly volatile
Short and Long Term Debt110.4 K124.2 K135.6 K
Slightly volatile

XTL Biopharmaceutica Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses2.2 M2.4 M2.6 M
Slightly volatile
Research Development83.8 K88.2 K778.7 K
Slightly volatile
Total Operating Expenses1.9 M2 M2.5 M
Slightly volatile
Depreciation And Amortization112.7 K179.1 K140.3 K
Pretty Stable
Selling General Administrative2.7 M1.7 M2.1 M
Slightly volatile
Selling And Marketing Expenses194.5 K204.7 K623.6 K
Pretty Stable
Non Recurring1.1 M763.2 K1.1 M
Slightly volatile

XTL Biopharmaceutica Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.2 M1.3 M2.3 M
Pretty Stable
End Period Cash Flow317.2 K333.9 K2.3 M
Slightly volatile
Sale Purchase Of Stock3.2 M5.6 M3.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio25.1623.9620.2472
Slightly volatile
PTB Ratio2.672.540.6029
Slightly volatile
Days Sales Outstanding11192.1475.9854
Slightly volatile
Book Value Per Share0.00880.00930.1599
Slightly volatile
Capex To Depreciation0.230.240.8083
Pretty Stable
PB Ratio2.672.540.6029
Slightly volatile
Inventory Turnover0.00.00.3506
Slightly volatile
Days Of Inventory On Hand18.1 M17.2 M14.5 M
Slightly volatile
Payables Turnover2.162.061.8006
Slightly volatile
Sales General And Administrative To Revenue3.913.733.5679
Slightly volatile
Research And Ddevelopement To Revenue0.240.250.4026
Slightly volatile
Capex To Revenue0.110.11970.1064
Slightly volatile
Cash Per Share0.00190.0020.0673
Slightly volatile
Days Payables Outstanding137144274.3 K
Pretty Stable
Intangibles To Total Assets0.770.740.2571
Slightly volatile
Current Ratio0.520.5511.4708
Pretty Stable
Receivables Turnover6.264.15.7782
Slightly volatile
Shareholders Equity Per Share0.00880.00930.1506
Slightly volatile
Debt To Equity0.02030.02290.0249
Slightly volatile
Capex Per Share1.0E-41.0E-43.0E-4
Slightly volatile
Revenue Per Share7.0E-48.0E-40.0092
Slightly volatile
Interest Debt Per Share2.0E-42.0E-41.0E-4
Slightly volatile
Debt To Assets0.01290.01450.0159
Slightly volatile
Graham Number0.01630.01060.0276
Slightly volatile
Operating Cycle68.572.111.1 M
Pretty Stable
Price Book Value Ratio2.672.540.6029
Slightly volatile
Days Of Payables Outstanding137144274.3 K
Pretty Stable
Company Equity Multiplier1.721.811.3321
Slightly volatile
Total Debt To Capitalization0.01980.02230.0243
Slightly volatile
Debt Equity Ratio0.02030.02290.0249
Slightly volatile
Quick Ratio0.520.5511.3538
Pretty Stable
Net Income Per E B T0.961.020.5789
Slightly volatile
Cash Ratio0.140.156.5076
Pretty Stable
Days Of Inventory Outstanding18.1 M17.2 M14.5 M
Slightly volatile
Days Of Sales Outstanding11192.1475.9854
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.820.931.0043
Slightly volatile
Price To Book Ratio2.672.540.6029
Slightly volatile
Fixed Asset Turnover2.062.175.8503
Slightly volatile
Debt Ratio0.01290.01450.0159
Slightly volatile
Price Sales Ratio25.1623.9620.2472
Slightly volatile
Asset Turnover0.04510.04750.0748
Slightly volatile
Gross Profit Margin0.00570.0060.118
Slightly volatile
Price Fair Value2.672.540.6029
Slightly volatile

XTL Biopharmaceutica Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap11.3 M10.8 M2.5 M
Slightly volatile

XTL Fundamental Market Drivers

XTL Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About XTL Biopharmaceutica Financial Statements

XTL Biopharmaceutica stakeholders use historical fundamental indicators, such as XTL Biopharmaceutica's revenue or net income, to determine how well the company is positioned to perform in the future. Although XTL Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in XTL Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on XTL Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in XTL Biopharmaceuticals Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue16.2 K15.4 K
Total Revenue405.9 K385.6 K
Cost Of Revenue403.2 K423.4 K
Stock Based Compensation To Revenue 0.53  0.40 
Sales General And Administrative To Revenue 3.73  3.91 
Research And Ddevelopement To Revenue 0.25  0.24 
Capex To Revenue 0.12  0.11 
Ebit Per Revenue(4.33)(4.55)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft
When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:
How To Invest In XTL
Details
Is XTL Stock a good investment?
Details
What is XTL Biopharmaceutica's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of XTL Biopharmaceutica Correlation against competitors.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Earnings Share
(0.90)
Revenue Per Share
0.1
Return On Assets
(2.41)
Return On Equity
(5.77)
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY